熱門資訊> 正文
Edwards Lifesciences 2026年每股收益指导范围包含共识
2025-12-04 23:07
- Edwards Lifesciences (EW) newly projected 2026 adjusted EPS guidance of $2.80-$2.95 includes to consensus figure of $2.86.
- The maker of products to treat advanced cardiovascular diseases also sees constant currency sales growth of 8%-10% next year.
- Transcatheter aortic valve replacement (TAVR) is projected at $4.6B-$4.9B; surgical sales at $1.05B-$1.13B; and sales of transcatheter mitral and tricuspid therapies (TMTT) of $740M-$780M.
- Edwards added it sees TMTT sales reaching $2B by 2030.
- The company also reaffirmed its 2025 adjusted EPS guidance of $2.56-$2.62. Consensus is $2.59.
More on Edwards Lifesciences
- Edwards Lifesciences Corporation (EW) Q3 2025 Earnings Call Transcript
- Edwards Lifesciences: Inflection Incoming, But When?
- Notable analyst calls this week: Meta, Boeing and Comcast among top picks
- Edwards Lifesciences trading flat despite 2025 guidance raise, Q3 beats
- Seeking Alpha’s Quant Rating on Edwards Lifesciences
推薦文章
華盛早報 | 黃金、白銀狂飆！特朗普「威脅」引地緣政治風險升溫；商業航天爆發！中國新增20萬顆衞星申請
港股周報 | 超配中國！高盛稱中國股市26年大漲15%至20%；阿里稱堅定加大淘寶閃購投入
2026年展望 | 智能駕駛元年或開啟！特斯拉Robotaxi引爆賽道，港美股哪些標的值得佈局？
美股機會日報 | 重磅大考！「非農+關税裁決」今夜同台亮相；Meta宣佈將投資核電廠，OKLO等核電股盤前飆升！
一周財經日曆 | 美國12月CPI攜手「恐怖數據」來襲；華爾街大行啟動Q4財報季，臺積電財報或炸場！4只港股新股即將上市
一周IPO | 吃大肉！本周六只新股上市大漲，MINIMAX暴漲109%；BBSB INTL孖展倍數超8900倍，位列史上第三
財報前瞻 | 臺積電Q4營收料衝破萬億新臺幣！大摩喊話績前買入，2026年股價還能「繼續飛」嗎？
MiniMax上市首日漲超60%，阿里、米哈遊等投資方「躺贏」
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
